KOL Perspectives: Perceptions of recent & upcoming data for key HBV pipeline agents
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Questions topics:
› Further Phase I data required for Roche’s capsid inhibitor RO7049389
› Replicor’s US trial plans and transition from IV to subcutaneous REP 2139
› Efficacy of Spring Bank’s inarigivir at 100mg in the Phase II ACHIEVE trial
› Expected role for inarigivir in HBV
› Efficacy of Arbutus’s Q2W IV ARB-1467
› ARB-1467, TDF + Peg-IFN trial design, potential for functional cure, & regimen acceptability
› Future development of Arbutus’s next-generation RNAi therapeutic AB-729For internal use only
Scope
› The insight briefing is based on Sociable Pharma’s analysis of primary research with our HBV key opinion leaders (KOLs)
› In total, we conducted interviews with 10 KOLs:
– 5 Europe-based & 5 N. America-based
– Interviews performed during Sept 2018
> KOL data is analyzed to produce:
– Charts summarizing KOL opinions
– Chart call-outs of key information & details
– KOL quotes
– Summary of KOL reporting trends
– Insight from Sociable Pharma's analysts
Key Highlights
Divided views on most relevant Phase I data required to differentiate RO7049389 from JNJ-6379 & ABI-H0731, with most concluding that Phase I data is insufficien
KOLs agree Replicor is making positive steps towards REP 2139’s development, but similar efficacy & safety must be demonstrated in the US trials and for the SC formulation
Disagreement between US and EU KOLs over the improvement in efficacy of inarigivir at the 100mg dose
Reasons to Buy
Combines Qualitative & semi-quantitative insight from key opinion leaders on "recent & upcoming data for key HBV pipeline agents"
Includes insight & recommendations from our disease-specific healthcare analysts
Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of HBV
Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion
Replicor
Spring Bank
Arbutus
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.